General InformationGinkgo Bioworks is a synthetic biology company headquartered in Boston, Massachusetts, with over 500 employees, founded in 2009, that uses computational design and cell engineering to create biological products at scale.
Funding & FinancialsThe company has raised over $1.5 billion in total funding, went public via SPAC merger with Soterium Capital in 2021 (ticker: DNA), and is backed by major investors including Andreessen Horowitz, Flagship Pioneering, and various strategic corporate investors.
Leadership & TeamGinkgo was founded by Jason Kelly, Reshma Shetty, Austin Che, and Tom Knight; Jason Kelly serves as CEO and brings background in bioengineering and computational synthetic biology.
Recent ActivityRecent developments include launching Biofy, a platform for cell engineering-as-a-service, expanding partnerships with major chemical and pharmaceutical companies, and advancing cell line engineering programs for improved protein production and biomanufacturing efficiency.